*Storage:
*Shipping:
Prucalopride is a high-affinity 5-HT4 receptor agonist。
Synonyms: R-93877
4.5
*For Research Use Only !
Change View
Size | Price | US Stock | Global Stock | In Stock |
1mg | łÇǶÊÊ | Inquiry | Inquiry | |
5mg | łÇď¶ÊÊ | Inquiry | Inquiry | |
10mg | łËǶÊÊ | Inquiry | Inquiry | |
50mg | ł§§¶ÊÊ | Inquiry | Inquiry | |
100mg | łÿó¶ÊÊ | Inquiry | Inquiry | |
250mg | łÇǧ¶ÊÊ | Inquiry | Inquiry | |
1g | łËďî¶ÊÊ | Inquiry | Inquiry | |
5g | łîďî¶ÊÊ | Inquiry | Inquiry |
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
łÇǶÊÊ
łÇď¶ÊÊ
łËǶÊÊ
ł§§¶ÊÊ
łÿó¶ÊÊ
łÇǧ¶ÊÊ
łËďî¶ÊÊ
łîďî¶ÊÊ
In Stock
- +
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 179474-81-8 |
Formula : | C18H26ClN3O3 |
M.W : | 367.87 |
SMILES Code : | O=C(C1=C(OCC2)C2=C(N)C(Cl)=C1)NC3CCN(CCCOC)CC3 |
Synonyms : |
R-93877
|
MDL No. : | MFCD09837787 |
InChI Key : | ZPMNHBXQOOVQJL-UHFFFAOYSA-N |
Pubchem ID : | 3052762 |
GHS Pictogram: | ![]() ![]() ![]() |
Signal Word: | Danger |
Hazard Statements: | H302-H319-H372-H410 |
Precautionary Statements: | P501-P273-P260-P270-P264-P280-P391-P314-P337+P313-P305+P351+P338-P301+P312+P330 |
Class: | 9 |
UN#: | 3077 |
Packing Group: | Ⅲ |
In Vitro:
Cell Line
| Concentration | Treated Time | Description | Reference |
M2-type bone marrow-derived macrophages | 20 ng/mL IL4 | 24 hours | To evaluate the effect of IL4 on BMDM polarization, results showed that IL4-treated BMDM expressed α7nAChR. | PMC6691854 |
CHO-K1 cells | 5 pM to 1 nM | 60 minutes | Evaluate the inhibitory effect of DLT on 5HT2AR | PMC5773938 |
Human colon circular muscle cells | 1 μM | Prucalopride usually increased the amplitude of cholinergically mediated contractions evoked by EFS, with smaller increases in the amplitude of the after-contractions. In the presence of L-NAME, the excitatory actions of prucalopride on cholinergic function were sometimes less clear. | PMC3838700 | |
Porcine right atrium | 0.1 nM to 10 μM | To investigate the chronotropic effects of 5-HT4 receptor agonists on porcine right atrium. Results showed that all agonists produced chronotropic effects when administered cumulatively, without fading. | PMC1615862 | |
Porcine left atrial pectinate muscles | 0.1 nM to 10 μM | 3 to 60 minutes | To investigate the inotropic and lusitropic effects of 5-HT4 receptor agonists on porcine left atrial pectinate muscles. Results showed that all agonists produced positive inotropic effects when administered noncumulatively, but only 5-HT produced positive inotropic effects when administered cumulatively. PDE inhibitor IBMX enhanced the inotropic effects of all agonists. | PMC1615862 |
In Vivo:
Species
| Animal Model
| Administration | Dosage | Frequency | Description | Reference |
Mice | Postoperative ileus (POI) model | Oral gavage | 1 or 5 mg/kg | Single dose 1.5 hours before or 22.5 hours after surgery | To evaluate the effect of Prucalopride on postoperative ileus, results showed that preoperative administration reduced intestinal inflammation and improved intestinal transit, while postoperative administration was ineffective. | PMC6691854 |
Male C57BL/6j mice | Wild-type and APP/V717I transgenic mice | Subcutaneous injection | 5 or 10 mg/kg | Single injection, mice were killed 90 min after the injection | To investigate the effect of 5-HT4 receptor agonists on sAPPα levels. Results showed that prucalopride significantly increased sAPPα levels in the hippocampus and cortex, and this increase was inhibited by the 5-HT4 receptor antagonist GR125487. | PMC2013878 |
Male C57BL/6J mice | DSS-induced colitis model | Oral | 5 mg/kg | Once daily for 7 days | Restored small intestinal motility and attenuated colitis | PMC11127033 |
129S6/SvEv mice | Contextual fear conditioning model | Intraperitoneal injection | 3 or 10 mg/kg | Single injection, behavioral tests conducted one week later | Prucalopride at 3 mg/kg attenuated learned fear and decreased stress-induced depressive-like behavior. | PMC6969048 |
C57BL/6 mice | MPTP-induced Parkinson’s disease model mice | Intraperitoneal injection | 1.5 or 3 mg/kg | Administered 2 h before each training session, twice in total | Prucalopride prevented the facilitation of contextual fear extinction in PD mice at days 2 and 3 in a dose-dependent manner, but did not have any significant effect on contextual fear extinction in control mice. | PMC6862438 |
Rats | Postoperative ileus model | Intravenous injection | 1 mg/kg and 5 mg/kg | Single dose one minute before the operation | To evaluate the effect of prucalopride on postoperative ileus. Results showed that prucalopride at 1 mg/kg significantly increased intestinal transit after laparotomy, but the effect was not significant at 5 mg/kg. | PMC1727718 |
Guinea pigs | Guinea pig isolated distal colon longitudinal muscle myenteric plexus (LMMP) | Oral | 0.1 to 10 mg/kg | Single dose, observed for 6 hours | Evaluate the effect of Prucalopride on faecal pellet output in guinea pigs. Results showed Prucalopride was most effective at 3 mg/kg. | PMC5773938 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03610217 | Scleroderma, Systemic ... More >> Sclerosis, Systemic Less << | Not Applicable | Not yet recruiting | October 2021 | Canada, Ontario ... More >> Saint Joseph's Health Care London Not yet recruiting London, Ontario, Canada, n6a 4v2 Contact: Janet E Pope, MD, MPH, FRCPSC 15196466332 Janet.Pope@sjhc.london.on.ca Contact: Andreu Fernandez-Codina 151964661023 doccodina@gmail.com Less << |
NCT02538367 | Functional Constipation | Phase 1 Phase 2 | Completed | - | Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Republic of Less << |
NCT01902537 | - | Completed | - | Korea, Republic of ... More >> Seoul, Korea, Republic of Less << | |
NCT02425774 | Postoperative Ileus | Phase 4 | Recruiting | December 2017 | Belgium ... More >> University hospitals Leuven Recruiting Leuven, Vlaams-Brabant, Belgium, 3000 Contact: Nathalie Stakenborg, MSc +32 16 342883 nathalie.stakenborg@med.kuleuven.be Contact: Kim Van Beek, MSc +32 16 341326 kim.vanbeek@med.kuleuven.be Principal Investigator: Guy Boeckxstaens, M.D. Less << |
NCT01655095 | Quality of Bowel Preparation f... More >>or the Colon Capsule Colon Capsule Completion Rates Colon Capsule Polyp Detection Less << | Phase 3 | Completed | - | Canada, Ontario ... More >> Hotel Dieu Hospital Kingston, Ontario, Canada Less << |
NCT00793429 | Healthy | Phase 1 | Completed | - | - |
NCT01870674 | Healthy | Phase 1 | Completed | - | Korea, Republic of ... More >> Inje Busan Paik hospital Busan, Korea, Republic of, 614-735 Less << |
NCT00485940 | Constipation | Phase 3 | Completed | - | - |
NCT00627692 | Constipation | Phase 2 | Completed | - | - |
NCT00577018 | Constipation | Phase 3 | Completed | - | - |
NCT01070615 | Chronic Constipation | PHASE3 | COMPLETED | - | University Hospital Antwerp, E... More >>degem, 2650, Belgium Less << |
NCT01330381 | Functional Constipation | Phase 3 | Completed | - | Netherlands ... More >> Academisch Medisch Centrum Amsterdam, Netherlands, 1105 AZ Less << |
NCT01869751 | Constipation | WITHDRAWN | 2025-12-18 | University Hospitals Leuven, L... More >>euven, Vlaams-Brabant, 3000, Belgium Less << | |
NCT01330381 | - | Completed | - | - | |
NCT00987844 | Chronic Constipation | PHASE3 | COMPLETED | - | Mayo Clinic, Rochester, Minnes... More >>ota, 55905, United States Less << |
NCT01036893 | Healthy Volunteers | Phase 1 | Completed | - | Germany ... More >> FOCUS GmbH Neuss, Germany, D-41460 Less << |
NCT00575614 | Constipation | Phase 2 | Completed | - | - |
NCT01134185 | Hepatic Impairment | Phase 1 | Completed | - | Russian Federation ... More >> Moscow, Russian Federation Less << |
NCT00483886 | Constipation | Phase 3 | Completed | - | - |
NCT00617513 | Constipation | Phase 2 | Completed | - | - |
NCT01147926 | Male Subjects With Chronic Con... More >>stipation Less << | Phase 3 | Completed | - | - |
NCT00598338 | Constipation | Phase 3 | Completed | - | - |
NCT02228616 | Constipation | Phase 4 | Completed | - | China ... More >> Beijing, China Bin Zhou, China Chongqing, China Hangzhou, China Nanjing, China Shanghai, China Tianjin, China Wuhan, China Zhengzhou, China Less << |
NCT01251822 | Constipation | Phase 3 | Completed | - | Romania ... More >> Pierrel Research Timisoara, Romania, RO-300244 Less << |
NCT01147926 | - | Completed | - | - | |
NCT00631813 | Constipation | Phase 2 | Completed | - | - |
NCT00596596 | Constipation | Phase 2 | Completed | - | - |
NCT01707667 | Chronic Constipation | Phase 4 | Completed | - | United States, Oklahoma ... More >> Oklahoma Foundation for Digestive Research Oklahoma City, Oklahoma, United States Belgium UNIVERSITY OF LEUVEN, UNVERSITY HOSPITAL, Gasthuisberg Leuven, Belgium, 3000 United Kingdom Barts Health NHS Trust Whitechapel, London, United Kingdom Less << |
NCT01424228 | Constipation | Phase 4 | Completed | - | - |
NCT01707667 | - | Completed | - | - | |
NCT00488137 | Constipation | Phase 3 | Completed | - | - |
NCT00576511 | Chronic Constipation | Phase 2 | Completed | - | - |
NCT01424228 | - | Completed | - | - | |
NCT00793247 | Chronic Intestinal Pseudo-Obst... More >>ruction Less << | Phase 2 | Completed | - | United Kingdom ... More >> Northwick Park Hospital London, United Kingdom Less << |
NCT02031081 | Gastroparesis ... More >> Diabetes Mellitus Less << | Phase 2 Phase 3 | Completed | - | Canada, Alberta ... More >> University of Calgary Calgary, Alberta, Canada, T2N 4Z6 Less << |
NCT03244553 | Ineffective Esophageal Motilit... More >>y|Dysphagia Less << | PHASE2 | COMPLETED | 2019-12-02 | University of Calgary, Calgary... More >>, Alberta, T2N 1N4, Canada Less << |
NCT01807000 | Healthy | Phase 1 | Completed | - | United States, Wisconsin ... More >> Covance Global Clinical Research Unit Inc. Madison, Wisconsin, United States, 53704 Less << |
NCT01864915 | Bowel Cleansing ... More >> Colon Capsule Completion Times Less << | Phase 3 | Completed | - | Canada, Ontario ... More >> Hotel Dieu Hospital Kingston, Ontario, Canada, K7L 5V7 Less << |
NCT02047045 | Constipation | Not Applicable | Completed | - | - |
NCT00488215 | Constipation | Phase 1 | Completed | - | - |
NCT01807000 | - | Completed | - | - | |
NCT03279341 | Chronic Constipation | Phase 4 | Completed | - | Belgium ... More >> TARGID Leuven, Belgium, 3000 Less << |
NCT02781493 | Prucalopride Plus Polyethylene... More >> Glycol in Bowel Preparation for Colonoscopyp Less << | Phase 4 | Unknown | March 2017 | China, Shandong ... More >> Department of Gastroenterology, Qilu Hospital, Shandong University Not yet recruiting Jinan, Shandong, China, 250012 Contact: Yanqing Li, MD, PhD 86-0531-82169236 liyanqing@sdu.edu.cn Less << |
NCT01117051 | Non-cancer Pain ... More >> Opioid Induced Constipation Less << | Phase 3 | Terminated(The study was stopp... More >>ed by the sponsor based on a non-safety related business priority decision) Less << | - | Belgium ... More >> Leuven, Belgium Less << |
NCT00903747 | Constipation | Phase 1 | Completed | - | - |
NCT01117051 | - | Terminated(The study was stopp... More >>ed by the sponsor based on a non-safety related business priority decision) Less << | - | - | |
NCT03676374 | GERD | Phase 4 | Recruiting | April 2021 | Belgium ... More >> UZ Leuven Recruiting Leuven, Belgium, 3000 Contact: Hannelore Geysen +32 (0)16 324921 hannelore.geysen@kuleuven.be Less << |
NCT01674166 | Constipation | Phase 1 | Completed | - | - |
NCT02947269 | Postoperative Ileus ... More >> Colorectal Surgery Postoperative Complications Less << | Phase 3 | Recruiting | February 2019 | New Zealand ... More >> University of Auckland Recruiting Auckland, New Zealand, 1023 Contact: Ian Bissett, MD, FRACS +649 3737599 ext 89821 i.bissett@auckland.ac.nz Less << |
NCT01692132 | Chronic Constipation | WITHDRAWN | 2025-12-14 | Makati City, Philippines|Manil... More >>a, Philippines|Marikina City, Philippines|Muntinlupa, Philippines|Quezon City, Philippines|San Juan, Philippines|Taguig, Philippines Less << | |
NCT02510976 | Gastroparesis | Phase 4 | Unknown | - | Belgium ... More >> University Hospitals Recruiting Leuven, Vlaanderen, Belgium, 3000 Contact: Jan Tack, M.D., Ph.D. +3216344225 jan.tack@med.kuleuven.be Principal Investigator: Jan Tack, M.D., Ph.D. Less << |
NCT02004652 | Postoperative Ileus | Phase 2 | Completed | - | China, Jiangsu ... More >> Department of Generay Surgery, Jinling hosptal, Medical School of Nanjing University Nanjing, Jiangsu, China, 210002 Less << |
NCT03572790 | Molecular Mechanisms of Pharma... More >>cological Action Depression Depressive Disorder Mood Disorders Mental Disorders Antidepressive Agents Cognition Less << | Not Applicable | Not yet recruiting | March 2020 | United Kingdom ... More >> University of Oxford Not yet recruiting Oxford, United Kingdom, OX3 7JX Less << |
NCT01116206 | Constipation | Phase 3 | Completed | - | Australia ... More >> Adelaide, Australia Box Hill, Australia Kingswood, Australia Kogarah, Australia Newcastle, Australia Parkville, Australia Prahran, Australia Sydney, Australia China Beijing, China Chongqing, China Guangzhou, China Hangzhou, China Hefei, China Jinan, China Nanjing, China Shanghai, China Wuhan, China Xian, China Korea, Republic of Busan, Korea, Republic of Dae-Gu, Korea, Republic of Deajun, Korea, Republic of Gwangju-Si, Korea, Republic of Iksan, Korea, Republic of Seoul, Korea, Republic of Taiwan Taipei, Taiwan Thailand Bamgkok, Thailand Bangkok, Thailand Less << |
NCT01674192 | Constipation | Phase 1 | Completed | - | - |
NCT01670669 | Constipation | Phase 1 | Completed | - | - |
NCT00487422 | Constipation | Phase 3 | Completed | - | - |
NCT02806206 | Gastrointestinal Hemorrhage ... More >> Crohn Disease Celiac Disease Intestinal Diseases Inflammatory Bowel Diseases Less << | Phase 4 | Unknown | May 2017 | Canada, British Columbia ... More >> Vancouver General Hospital Vancouver, British Columbia, Canada, V5Z 1M9 Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() | 1mg | 5mg | 10mg |
1 mM 5 mM 10 mM | 2.72mL 0.54mL 0.27mL | 13.59mL 2.72mL 1.36mL | 27.18mL 5.44mL 2.72mL |
Tags: Prucalopride | 5-HT Receptor | Apoptosis | Autophagy | Serotonin Receptor | 5-hydroxytryptamine Receptor | pseudo-intestinal obstruction | 5-HT4 receptor agonist | intestinal motility | PI3K/AKT/mTor pathway | chronic constipation | pseudo-intestinal obstruction | 179474-81-8
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL